BPC May 20 update

​Surface Oncology SURF collaboration with Merck +46%; Galapagos GLPG late-stage data -11% AH

Price and Volume Movers

Surface Oncology (NASDAQ:SURF) shares closed up 46% to $3.88 following its announcement of a collaboration with Merck (NYSE:MRK) to evaluate the safety and efficacy of Surface's SRF617, with Merck's Keytruda, initially to be trialled in patients with solid tumors, with a focus on patients with gastric cancer.

Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Nasdaq: GLPG) announced data from its Phase 2b/3 SELECTION trial evaluating the efficacy and safety of filgotinib in patients with moderately to severely active ulcerative colitis (UC). The Filgotinib 200 mg achieved all primary endpoints in the study. However, the 100 mg dose did not achieve statistically significant clinical remission at Week 10. Shares of Galapagos are trading down 11% to $197.50 after hours.

Oncternal Therapeutics, Inc. (Nasdaq: ONCT) announced a registered direct offering for the sale of 1,943,636 shares of its common stock, at a purchase price of $2.5725 per share, together with a concurrent private placement of unregistered warrants to purchase up to an aggregate of 971,818 shares of its common stock. The gross proceeds from this offering are expected to be approximately $5m.

Flexion Therapeutics, Inc. (NASDAQ:FLXN) announced it has commenced an underwritten public offering of $75m of shares of its common stock. Shares are trading down 6% to $10.24 after hours.

scPharmaceuticals Inc. (NASDAQ:SCPH) shares are trading down 12% to $9.49 after hours after it also announced that it has commenced an underwritten public offering of shares of its common stock.


Major price movers (stocks priced > $1.00, volume > 50k):

Refer to the BioPharmCatalyst Biotech Stocks page for Top 10 Gainers/Losers/Unusual Volume:


Atara Biotherapeutics, Inc. (ATRA): $14.27; +29%.

NuCana plc (NCNA): $7.37; +27%.

Atossa Genetics Inc. (ATOS): $2.20; +26%.

Satsuma Pharmaceuticals, Inc. (STSA): $26.00; +26%.

Altimmune, Inc. (ALT): $6.06; +23%.


Acer Therapeutics Inc. (ACER): $3.88; -14%.

I-Mab (IMAB): $22.70; -13%.

Tiziana Life Sciences PLC (TLSA): $4.75; -12%.

Navidea Biopharmaceuticals, Inc (NAVB): $1.29; -12%.

Timber Pharmaceuticals, Inc. (TMBR): $3.65; -11%.

Pipeline updates below:

Pipeline Database Updates

Drug Stage Catalyst Market Cap

ALDX – Aldeyra Therapeutics Inc.
Ovarian cancer

Phase 2 Phase 2 enrolment to be completed in June 2020.
$146.6 million

ALDX – Aldeyra Therapeutics Inc.

Phase 1 IND filing due 3Q 2020.
$146.6 million

BLRX – BioLineRx Ltd.
Stem-cell mobilization for autologous transplantation

Phase 3 Phase 3 top-line data due 2H 2020.
$23.5 million

BLRX – BioLineRx Ltd.
BL-8040 in combination with KEYTRUDA - COMBAT trial
Pancreatic cancer

Phase 2 Phase 2 PFS and OS data due mid-2020.
$23.5 million

CDTX – Cidara Therapeutics Inc.
Rezafungin (CD101) ReSPECT

Phase 3 Phase 3 dosing of first patient announced May 20, 2020.
$147.5 million

GLPG – Galapagos NV
Filgotinib - SELECTION
Ulcerative colitis

Phase 2/3 Phase 2b/3 data released May 20, 2020. 200mg dose met primary endpoint. 100mg did not meet clinical remission endpoint.
$13.1 billion

INO – Inovio Pharmaceuticals Inc.
Coronavirus COVID-19 vaccine

Phase 1 Phase 1 interim data due June 2020. Phase 2/3 trial to commence July/August 2020.
$2.3 billion

KPTI – Karyopharm Therapeutics Inc.
Selinexor - BOSTON
Multiple myeloma

Phase 3 sNDA filing announced May 20, 2020.
$1.4 billion

MDWD – MediWound Ltd.
Severe burns

BLA Filing BLA filing due mid-2020.
$55.8 million

MDWD – MediWound Ltd.
Venous leg ulcers (VLU’s)

Phase 2 Phase 2 interim assessment due 1H 2021.
$55.8 million

NRBO – NeuroBo Pharmaceuticals Inc.

Phase 1 Phase 1 trial to be initiated 1Q 2021.
$217.2 million

ORIC – Oric Pharmaceuticals Inc.
ORIC-101 and Xtandi (enzalutamide)
Prostate cancer

Phase 1b Phase 1b interim data due 1H 2021.
$867.8 million

SURF – Surface Oncology Inc.
SRF617 and Keytruda
Solid tumors

Phase 1b Phase 1a/b trial planned.
$144.7 million

TYME – Tyme Technologies Inc.
Pancreatic cancer

Phase 3 Phase 3 trial to complete enrolment by late-2020 to early-2021.
$192.9 million